Clinical trials: Specific Immunotherapy
Diffuse Intrinsic Pontine Glioma, Glioma
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT02960230
- Testing
- K27M peptide, Nivolumab
- Where
- 15 sites in United States, Switzerland
- Volunteers
- 50 people
- Sponsor
- Sabine Mueller, MD, PhD
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
This phase I/II trial studies the side effects and how well localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy works in treating patients with Merkel cell…
- Trial name
- NCT02584829
- Testing
- Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Fred Hutchinson Cancer Center
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Head and Neck Squamous Cell Cancer
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck…
- Trial name
- NCT02163057
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Inovio Pharmaceuticals
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02706405
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of genetically engineered lymphocyte therapy and to see how well it works after peripheral blood stem cell transplant (PBSCT) in treating patients with high-risk…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT01318317
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Filgrastim, Genetically Engineered Lymphocyte Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Melanoma
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
The purpose of this study is to investigate the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing…
- Trial name
- NCT01213472
- Testing
- GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 24 sites in Australia, Austria and 6 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
HER2/Neu Positive, HLA-A2 Positive Cells Present
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor…
- Conditions
- HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00194714
- Testing
- HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
This is a prospective open label, controlled, randomized study to test the safety and efficacy of active specific immunotherapy with tecemotide (L-BLP25) for the treatment of subjects with Stage IIIB or Stage IV non-small cell…
- Trial name
- NCT00157209
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC)
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Allergy
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
- Trial name
- NCT00310466
- Testing
- Sublingual immunotherapy
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- ALK-Abelló A/S
Asthma, Perennial Allergic Rhinitis
Subcutaneous Immunotherapy for Mouse in Adults
This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity.
- Trial name
- SCITMO (NCT02532179)
- Testing
- Mouse Allergenic Extract
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Background: Flutamide is an approved drug for prostate cancer that blocks the effects of testosterone on prostate cancer cells and may slow the progression of the disease.
- Trial name
- NCT00450463
- Testing
- Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Allergic Asthma
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that…
- Trial name
- NCT00267202
- Testing
- Omalizumab, Immunotherapy
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03277729
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both IMP321/LAG-3 and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety and…
- Trial name
- LAG-3/IMP321 (NCT01308294)
- Testing
- 2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 "vaccine injections" in distinct limbs
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Pancreatic Cancer, Resected
Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and Understand any possible side effects of the…
- Trial name
- NCT02261714
- Testing
- TG01
- Where
- 5 sites in Norway, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Targovax ASA
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon